Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines

Table 3

Multivariate analysis of PC risk and HGPCa risk according to the treatment with statins and aspirin respect no treatment.

Treatment	PCa detection^*	value	HGPCa detection^*	value
Age (years)	1.066 (1.049–1.084)	0.001	1.100 (1.071–1.130)	0.001
BMI (Kg/m^2)	1.018 (0.001–1.047)	0.189	0.989 (0.948–1.032)	0.616
PSA (ng/mL)	1.024 (1.008–1.041)	0.004	1.038 (1.027–1.049)	0.001
DRE (positive versus negative)	1.219 (1.028–1.428)	0.001	1.266 (0.879–1.822)	0.205
Statin (yes versus no)	0.910 (0.728–11.137)	0.430	1.092 (0.725–1.646)	0.637
Aspirin (yes versus no)	1.150 (0.824–1.604)	0.439	1.835 (1.068–3.155)	0.028
Statins + aspirin (yes versus no)	0.616 (0.467–0.812)	<0.001	3.059 (1.894–4.939)	<0.001
Time on statins (months)	0.998 (0.955–1.000)	0.063	1.005 (1.000–1.010)	0.034
Time on aspirins (months)	0.984 (0.979–0.990)	<0.001	1.033 (1.020–1.047)	<0.001

BMI: body mass index, PSA: prostate specific antigen, and DRE: digital rectal examination. Values expressed as odds ratio (95% confidence interval).